<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Albireo Pharma, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Albireo Pharma, Inc.

    Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Ron Cooper
    • FOUNDED
      2003
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    ShockWave Medical, Inc.

    ShockWave Medical, Inc.

    Shockwave Medical, headquartered in Santa Clara, California is a medical device co...

    Shockwave Medical, headquartered in Santa Clara...

    Filing Type:    PU
    Menlo Therapeutics Inc.

    Menlo Therapeutics Inc.

    We are a late stage biopharmaceutical company focused on the development and comme...

    We are a late stage biopharmaceutical company f...

    Filing Type:    PU
    EyePoint Pharmaceuticals, Inc.

    EyePoint Pharmaceuticals, Inc.

    EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed ...

    EyePoint Pharmaceuticals, Inc. is a specialty b...

    Filing Type:    PU
    Ionis Pharmaceuticals, Inc.

    Ionis Pharmaceuticals, Inc.

    Ionis is a sustainably profitable, multi-product company with a pipeline of more t...

    Ionis is a sustainably profitable, multi-produc...

    Filing Type:    PU
    Millendo Therapeutics, Inc.

    Millendo Therapeutics, Inc.

    Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused ...

    Millendo Therapeutics is a late-stage biopharma...

    Filing Type:    PU
    TCR2 Therapeutics Inc.

    TCR2 Therapeutics Inc.

    TCR² is an innovative immunotherapy company developing the next generation of T c...

    TCR² is an innovative immunotherapy company de...

    Filing Type:    PU
    Dicerna Pharmaceuticals, Inc.

    Dicerna Pharmaceuticals, Inc.

    Dicerna is a biopharmaceutical company focused on the discovery and development of...

    Dicerna is a biopharmaceutical company focused ...

    Filing Type:    PU
    Cara Therapeutics, Inc.

    Cara Therapeutics, Inc.

    Cara Therapeutics is a clinical-stage biopharmaceutical company focused on develop...

    Cara Therapeutics is a clinical-stage biopharma...

    Filing Type:    PU
    Mirum Pharmaceuticals, Inc.

    Mirum Pharmaceuticals, Inc.

    Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused o...

    Mirum Pharmaceuticals Inc. is a clinical-stage ...

    Filing Type:    PU
    Evoke Pharma, Inc.

    Evoke Pharma, Inc.

    Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused pr...

    Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialt...

    Filing Type:    PU
    Edesa Biotech, Inc.

    Edesa Biotech, Inc.

    Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...

    Edesa Biotech Inc. is a clinical-stage biopharm...

    Filing Type:    PU
    Novan, Inc.

    Novan, Inc.

    Novan, Inc. is a clinical development-stage biotechnology company focused on lever...

    Novan, Inc. is a clinical development-stage bio...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.